Added to YB: 2026-07-13
Pitch date: 2026-05-04
CUE [bearish]
Cue Biopharma, Inc.
-21.67%
current return
Author Info
No bio for this author
Company Info
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders.
Market Cap
$154.5M
Pitch Price
$30.23
Price Target
N/A
Dividend
N/A
EV/EBITDA
-8.97
P/E
-7.05
EV/Sales
4.29
Sector
Biotechnology
Category
special_situation
Cue Biopharma, Inc. - $CUE
CUE (short): Cash-burning biotech, $27M cash vs $40M+ annual burn, going concern warning. Licensed lead oncology assets to ImmunoScape (fire sale, admitting no Big Pharma interest); pivoted to early-stage autoimmune/allergy. $21.9M Q4 collab rev one-time. Post 1-for-30 split & $30M PIPE at $11 (no named investors) + $13M ATM = coordinated dilution into 106% rally to $30.42. Target ~60% drop/month, full position 4% equity.
Read full article (6 min)